反应详情

2-[butyl-(3-chloro-benzoyl)-amino]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine-3-carboxylic acid (130 mg, 0.45 mmol), EDCI (72.9 mg, 0.38 mmol, 1.0 eq.) and HOAt (4.7 mg, 0.035 mmol, 0.1 eq.) were dissolved in DCM (3.5 mL). ortho-phenetidine (51.5 μL, 0.35 mmol) was added thereto and the solution was stirred for 16 hours at room temperature. The solvent was removed under vacuum, EtOAc (30 mL) was added thereto and the organic phase was washed a plurality of times with a 0.5 M solution of KHSO4 in water (30 mL) and saturated aqueous NaHCO3 solution (35 mL). The aqueous phases were shaken out a plurality of times with ethyl acetate. The combined organic phases were washed with saturated aqueous NaCl solution (40 mL) and dried over sodium sulphate, and the solvent was removed under vacuum. The untreated product was purified by column chromatography (SiO2, DCM→DCM/MeOH 98/2). 130 mg (73%) of the desired product 2-[butyl-(3-chloro-benzoyl)-amino]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine-3-carboxylic acid were obtained.

1. customThe solvent was removed under vacuum, EtOAc (30 mL)
2. additionwas added
3. washthe organic phase was washed a plurality of times with a 0.5 M solution of KHSO4 in water (30 mL) and saturated aqueous NaHCO3 solution (35 mL)
4. stirringThe aqueous phases were shaken out a plurality of times with ethyl acetate
5. washThe combined organic phases were washed with saturated aqueous NaCl solution (40 mL)
6. dry with materialdried over sodium sulphate
7. customthe solvent was removed under vacuum
8. customThe untreated product was purified by column chromatography (SiO2, DCM→DCM/MeOH 98/2)